

Brain Tumour (primary) and metastases, Guideline Committee meeting 5

Date: Thursday 9th March 2017

Location: Royal College of Obstetricians and Gynaecologists (RCOG)

Minutes: Final

Committee members present	
Eileen Andrews	Present for items 1-8
Sebastian Brandner	Present for items 1-8
Alison Cameron	Present for items 1-8
Catherine Derbyshire	Present for items 1-8
Sara Erridge	Present for items 1-8
Zoe Faulkner	Present for items 1-8
Sarah Jefferies	Present for items 1-8
Ingela Oberg	Present for items 1-8
Sara Robson	Present for items 1-8
Dr Tom Roques (Chair)	Present for items 1-8
Stuart Smith	Present for items 1-8
David Summers	Present for items 1-8
John Graham	Present for items 1-8
Jeremy Rees	Present for items 1-8
Isabella Robbins	Present for items 1-8
Helen Bullbeck	Present for items 1-8
Colin Watts	Present for items 1-8
David Summers	Present for items 1-8
NGA staff	
Stephanie Arnold, Information Scientist	Present for items 1-8
Alex Bates, Guideline Lead	Present for items 1-8
Eva Gonzalez, Systematic Reviewer	Present for items 1-8
James Hawkins, Health Economist	Present for items 1-8
Kelly Williams, Assistant systematic reviewer	
Victoria Rowlands, Project Manager	Present for items 1-8
NICE staff	
Katie Perryman Ford	Present for items 1-8
Apologies	
Garth Cruickshank	

1. Welcome, housekeeping, introductions, apologies

Welcome, housekeeping, introductions and apologies

Update of Expenses policy

2. Confirmation of matter under discussion, and declarations of interest

Members of the Committee declared Declarations of interest, these are noted in the above.

Name	Job title, organisation	Declaration of interest	Type of interest	Decision taken
Alison Cameron		Elekta has been invoiced by UH Bristol for the Bristol Gamma Knife team to be interviewed (including myself) that Elektra were making.	Financial, non-personal, nonspecific.	Declared and participated

3. Lay member forum

No specific issues were raised by the Lay members of the Committee.

4. Protocol sign off- Imaging strategy “What is the most effective imaging strategy in newly diagnosed glioma and meningioma?”

The sub group and guideline lead took the rest of the committee through the above protocol, slight changes were made and the committee signed off on this protocol.

5. Presenting evidence – Initial High grade Glioma “Following surgery, what is the optimal management (radiotherapy, chemotherapy, combinations of these, or other therapies such as metformin or tumour-treating fields) of initial high-grade glioma?” (presentation 1)

Kelly Williams took the group through the evidence on the above topic question.

6. Drafting recs review – Initial High grade glioma “Following surgery, what is the optimal management (radiotherapy, chemotherapy, combinations of these, or other therapies such as metformin or tumour-treating fields) of initial high-grade glioma?”

Drafting recs review – Initial High grade glioma

“Following surgery, what is the optimal management (radiotherapy, chemotherapy, combinations of these, or other therapies such as metformin or tumour-treating fields) of initial high-grade glioma?”

7. Protocol sign off- Molecular Markers “What are the most useful molecular markers to determine prognosis /guide treatment for gliomas?”

The sub group and guideline lead took the rest of the committee through the above protocol, slight changes were made and the committee, however the Committee were unable to sign this off in the meeting, this will be returned to.

8. Protocol sign off- Neuro Rehab “What are the facilitators and barriers to providing appropriate neurological rehabilitation assessment in people with brain tumours (primary) and brain metastases?”

The sub group and guideline lead took the rest of the committee through the above protocol, slight changes were made and the committee signed off on this protocol.

9. What is the most effective surveillance protocol (including no surveillance) for detecting late effects of treatment for glioma, meningioma or brain metastases

The sub group and guideline lead took the rest of the committee through the above protocol, slight changes were made and the committee signed off on this protocol.

10. Health Economic Prioritisation

James Hawkins presented on prioritising Health Economic topics and how these will be presented over the coming meetings.

11. Protocol confirmation – Follow up

5a) “What is the most effective follow-up protocol (including duration, frequency and tests) to detect recurrence after treatment for glioma?”

5b) What is the most effective follow-up protocol (including duration, frequency and tests) to detect recurrence after treatment for meningioma?

5c) What is the most effective follow-up protocol (including duration, frequency and tests) to detect intracranial recurrence after treatment for brain metastases?

The sub group and guideline lead took the rest of the committee through the above protocol, slight changes were made and the committee signed off on this protocol.

12. Protocol confirmation – Care needs “What are the health and social care support needs of people with brain tumours (primary) and brain metastases and their families and carers?”

The sub group and guideline lead took the rest of the committee through the above protocol, slight changes were made and the committee signed off on this protocol.

13. AOB and close

No other business was raised. The next committee meeting will be held on the 28th April 2017.

The chair closed the meeting.